Norms for Clinical Use of CXM, a Real-Time Marker of Height Velocity.

ABSTRACT:

Context

Height velocity (HV) is difficult to assess because growth is very slow. The current practice of calculating it from measurements taken at several-month intervals is insufficient for managing children with growth disorders. We identified a bone growth by-product (collagen X biomarker, CXM) in blood that in preliminary analysis in healthy children correlated strongly with conventionally determined HV and displayed a pattern resembling published norms for HV vs age.

Objective

The goal was to confirm our initial observations supporting the utility of CXM as an HV biomarker in a larger number of individuals and establish working reference ranges for future studies.

Design, settings, and participants

CXM was assessed in archived blood samples from 302 healthy child

SUBMITTER: Coghlan RF 

PROVIDER: S-EPMC7765635 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature